Alantra advises 90TEN on its sale to Envision Pharma Group
Alantra has advised the shareholders of 90TEN, the global healthcare communications consultancy, on the sale of the business to Envision Pharma Group. Envision Pharma Group is a global provider of evidence-based communication services and industry-leading technology solutions.
90TEN will retain its brand and service offering, bringing its insight-led behavioral science model Feel-Think-Do™ to a broad spectrum of Envision Pharma Group’s communications solutions. This partnership will enrich Envision Pharma Group’s global reach in medical affairs, which include its flagship technology, iEnvision®, together with strategic publications planning and delivery, medical strategy and communications, market access, and creative and digital solutions. In adding 90TEN’s strengths in behavioral science, creativity, and insight-driven communications, this acquisition will deliver an enhanced service offering to the Group’s global client base.
Based in London, 90TEN works with over half of the top 20 pharma companies in the world serving clients across Europe and North America. The acquisition of 90TEN will bring the total number of Envision Pharma Group employees to around 800 across 14 offices and four continents. 90TEN will be managed from its London headquarters by the existing management team, including co-founder Paul Tanner, and Managing Directors Peter Impey and Alison Doughty.
Alantra’s Healthcare team was appointed due to its significant experience of working with healthcare communications businesses, identifying strategic partners and securing investment solutions. Anthony Harrington, partner at Alantra, led the deal, supported by director Tom Cowap and associate Santiago San Antonio Alonso.
Anthony Harrington, partner at Alantra, commented, “90TEN is a multiple-award winning healthcare communications consultancy and a leading light in the sector. We worked with the owners of 90TEN to explore a broad range of options that would help to accelerate their future growth.”
He added: “This deal reflects a number of wider trends we are seeing in the healthcare communications and consulting sector. The services provided by 90TEN are highly sought after by clients, making them attractive acquisition targets to larger strategic competitors and private equity-backed businesses like Envision Pharma Group.”
90TEN’s Chairman, Paul Tanner, commented, “Anthony and the Alantra team took the time to truly understand our culture and values, and what we were looking for in a future partnership. They presented us with strategic options that would best fit 90TEN’s long-term aspirations and the needs of our team, company and clients. We now have a partner in Envision Pharma Group who shares our vision and values and will provide global support to accelerate our plans to extend into more markets and reach more audiences. They are the perfect strategic and cultural fit for 90TEN and we are very excited about the growth opportunities that this partnership will bring to both organisations.”
Oct 2020Buy-side advisoryOct 2020SECTOR HealthcareService M&A
Oct 2020InvestmentOct 2020SECTOR HealthcareService Strategic Advisory
Sep 2020Buy-side advisoryValue CHF 435 millionSep 2020SECTOR HealthcareService M&AValue CHF 435 million
Sep 2020Sell-side advisorySep 2020SECTOR HealthcareService M&A